{"analyses":[{"ciLowerLimit":"0.65","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.00","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.049","paramType":"Hazard Ratio (HR)","paramValue":"0.81","statisticalComment":"A log-rank test, stratified according to prior or no prior tamoxifen therapy.","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.2","upperLimit":"45.0","value":"41.3"},{"groupId":"OG001","lowerLimit":"43.4","upperLimit":"55.7","value":"47.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"345"},{"groupId":"OG001","value":"349"}],"units":"Participants"}],"description":"From date of randomization to date of death due to any cause. Patients last known to be alive are censored at last date of contact.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive oral anastrozole once daily on days 1-28.\n\nanastrozole: Given orally","id":"OG000","title":"Arm I Anastrozole"},{"description":"Patients receive oral anastrozole as in arm I. Patients also receive fulvestrant intramuscularly on days 1, 14, and 28 during course 1 and then on day 28 of the subsequent courses.\n\nanastrozole: Given orally\n\nfulvestrant: Given intramuscularly","id":"OG001","title":"Arm II Anastrozole and Fulvestrant"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Every 4 weeks while on treatment. Then every 3 months until progression, then six months for two years then annually until four years or until death, which ever occurs first.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}